Resonance Health Lifts Profit Guidance 30% as Margins Hit 16.3% on Automation
Resonance Health lifts FY26 profit guidance by 30% as margins expand
Resonance Health has upgraded its FY26 underlying EBITDA guidance to approximately $2.6 million, representing a 30% increase from previous guidance of $2.0 million. The upgrade reflects continued strong operational performance, improved operating leverage, and margin expansion across the company’s clinical trials and Software-as-Medical Devices (SaMD) business.
The underlying EBITDA margin is now expected to reach approximately 16.3%, up from previous guidance of 11.8%. This margin expansion is driven by operational factors including improved cost efficiencies and a growing contribution from higher-margin activities, rather than one-off items.
Revenue guidance has been refined to approximately $16.0 million from $17.0 million, but this reduction primarily reflects timing of revenue recognition associated with a major clinical trial agreement rather than lost business. The contracted revenue for this clinical trial agreement remains at approximately $13.8 million, with a greater proportion now expected to be recognised in FY27.
| Metric | Previous Guidance | Updated Guidance |
|---|---|---|
| Revenue | ~$17.0 million | ~$16.0 million |
| Underlying EBITDA | ~$2.0 million | ~$2.6 million |
| Underlying EBITDA margin | ~11.8% | ~16.3% |
When big ASX news breaks, our subscribers know first
What is EBITDA and why does margin expansion matter for investors?
EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortisation. It measures a company’s operating profitability by showing how much profit the core business generates before accounting for financing costs, tax obligations, and non-cash expenses.
EBITDA margin expansion indicates the company is converting a higher percentage of revenue into profit. For Resonance Health, the margin improvement from 11.8% to 16.3% demonstrates that even with slightly lower revenue, stronger margins deliver better bottom-line outcomes.
This reflects operating leverage, which is the ability to grow profits faster than revenue as fixed costs are spread across a larger operational base. When a company achieves margin expansion on lower revenue, it signals disciplined cost management and an improving business mix. Investors should monitor margin trajectory as a leading indicator of how profitability will scale as the business grows.
Revenue timing explained — clinical trial contract remains intact
The approximately $1.0 million reduction in revenue guidance relates to timing of revenue recognition associated with a major clinical trial agreement. The contracted revenue for this clinical trial agreement remains at approximately $13.8 million, with a greater proportion of this revenue now expected to be recognised in FY27 rather than FY26.
This represents revenue deferred, not revenue lost. The contracted revenue base remains strong, with no contract cancellation or scope reduction. The timing shift means FY27 benefits from this revenue rolling forward, providing visibility into the following financial year’s performance.
Four drivers behind the profit upgrade
The upgraded EBITDA guidance is driven by multiple operational factors:
-
Increased contribution and operating leverage from the Software-as-Medical Devices (SaMD) segment, particularly in GLP-1 driven metabolic and obesity-related imaging endpoints for clinical trials
-
Positive contribution from TrialsWest investigator site network, including expanded capacity through new clinic openings
-
Continued strong performance in Resonance Clinical (CRO service provision), including execution of major clinical trial contracts
-
Benefits from continued automation, process and workflow improvements, and disciplined resource allocation
The upgrade stems from multiple operational levers rather than a single contract or one-off benefit, indicating broad-based business improvement. SaMD exposure to GLP-1 obesity drug trials positions the company in a high-growth therapeutic area, whilst automation investments are translating directly into margin improvement.
Medium-term targets remain in focus
The upgraded margin of approximately 16.3% represents a meaningful milestone toward the company’s medium-term objective of scaling revenue toward approximately $30 million and achieving an underlying EBITDA margin of approximately 25%.
The FY26 result validates the margin expansion thesis ahead of schedule, providing a roadmap for investors to track execution against stated targets.
Medium-Term Targets
Revenue: ~$30 million | EBITDA margin: ~25%
The next major ASX story will hit our subscribers first
Outlook and growth positioning
Resonance Health’s forward positioning is supported by:
-
A diversified business model across complementary clinical trials, SaMD, and clinical services segments
-
A strong contracted revenue base within the clinical trials pipeline
-
Continued expansion opportunities across the global clinical trial ecosystem
-
A growing contribution from higher-margin products and services
-
Ongoing investment in automation and AI-driven technologies to enhance scalability
The company continues to target underlying EBITDA margin expansion over the medium-term as operating leverage increases and the business scales.
Multiple growth vectors reduce single-point-of-failure risk for investors. The ongoing investment in AI and automation suggests margin expansion has further runway beyond the current FY26 guidance, particularly as the company scales toward its medium-term revenue target of $30 million.
Don’t Miss the Next Healthcare Breakthrough
Join 20,000+ investors getting FREE breaking ASX news delivered to your inbox within minutes, complete with in-depth analysis. Click the “Free Alerts” button at StockWire X to start receiving alerts the moment market-moving healthcare news breaks.